melatonin has been researched along with MS (Multiple Sclerosis) in 91 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin is a neurohormone secreted predominantly by the pineal gland that is demonstrated to be associated with the pathogenesis of multiple sclerosis (MS)." | 9.41 | Clinical efficacy and safety of melatonin supplementation in multiple sclerosis: a systematic review. ( Gholipour-Khalili, E; Hakimzadeh, Z; Hamidi, S; Kakaei, J; Morsali, S; Naseri, A; Sabahi, Z; Sanaie, S; Talebi, M, 2023) |
| "From the 26 patients who completed the study, there was no significant difference observed in the signs or symptoms of nocturia when taking 2 mg melatonin compared to placebo." | 9.27 | Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS). ( Canham, L; Cotterill, N; Cottrell, D; Delgado, D; Drake, MJ; Homewood, J; Inglis, K; Johnson, L; Kisanga, MC; Owen, D; White, P, 2018) |
| "This study will evaluate whether melatonin reduces the frequency of nocturia episodes in MS patients, and therefore whether 'Circadin' has the potential to reduce LUTS and fatigue, and improve cognition and overall quality of life." | 9.24 | Protocol for a randomized, double blind, placebo controlled, crossover trial of Melatonin for treatment of Nocturia in adults with Multiple Sclerosis (MeNiMS). ( Canham, L; Cotterill, N; Cottrell, D; Delgado, D; Drake, MJ; Inglis, K; Owen, D; White, P, 2017) |
| " Such pathophysiological processes include increases in oxidative and nitrosative stress, pro-inflammatory immune responses, especially T helper (Th)17 cell proliferation and activation, tryptophan catabolites, pain, fatigue and increased levels of depression." | 8.93 | Multiple Sclerosis, Gut Microbiota and Permeability: Role of Tryptophan Catabolites, Depression and the Driving Down of Local Melatonin. ( Anderson, G; Rodriguez, M; Wootla, B, 2016) |
| "Conflicting results on melatonin synthesis in multiple sclerosis (MS) have been reported due to variabilities in patient lifestyles, which are not considered when supplementing melatonin." | 8.31 | Inhibiting nighttime melatonin and boosting cortisol increase patrolling monocytes, phagocytosis, and myelination in a murine model of multiple sclerosis. ( Ghareghani, M; Laflamme, N; Pons, V; Rivest, S; Zibara, K, 2023) |
| "Melatonin has been related to the pathophysiology of multiple sclerosis (MS), and its anti-inflammatory and immunomodulatory properties have been proved in numerous neurodegenerative diseases." | 8.12 | Protective effects of melatonin on changes occurring in the experimental autoimmune encephalomyelitis model of multiple sclerosis. ( Agüera, E; Caballero-Villarraso, J; Escribano, BM; Gascón, F; Giraldo, AI; Muñoz-Jurado, A; Paz-Rojas, E; Santamaría, A; Túnez, I; Valdelvira, ME, 2022) |
| "Melatonin (MT), a neurohormone with immunomodulatory properties, is one of the metabolites produced in the brain from tryptophan (TRP) that has already strong links with the neuropathogenesis of Multiple sclerosis (MS)." | 8.12 | Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway. ( Ejtemaei-Mehr, S; Ghahremani, MH; Ghanbari, A; Ghazi-Khansari, M; Guillemin, GJ; Jand, Y, 2022) |
| "Multiple sclerosis (MS) is a progressive chronic inflammatory autoimmune disease of the myelin sheath, and melatonin is a powerful antioxidant and anti-inflammatory agent." | 7.96 | Neuroprotective Effects of Melatonin during Demyelination and Remyelination Stages in a Mouse Model of Multiple Sclerosis. ( Abo Taleb, HA; Alghamdi, BS, 2020) |
| "A growing body of evidence indicates the role of melatonin (MT) in the pathogenesis of multiple sclerosis (MS): It modulates immune function, alleviates oxidative stress and it is linked to seasonality of MS relapse." | 7.91 | Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis. ( Akgün, K; Geiger, M; Kästner, A; Kern, S; Paucke, M; Ziemssen, T, 2019) |
| " Serum levels of melatonin decrease in MS patients who are also at risk of osteoporosis." | 7.88 | Melatonin therapy reduces the risk of osteoporosis and normalizes bone formation in multiple sclerosis. ( Arnoult, D; Farhadi, N; Ghareghani, M; Scavo, L; Zibara, K, 2018) |
| "Melatonin has a beneficial role in adult rat models of multiple sclerosis (MS)." | 7.85 | Melatonin exacerbates acute experimental autoimmune encephalomyelitis by enhancing the serum levels of lactate: A potential biomarker of multiple sclerosis progression. ( Dokoohaki, S; Farhadi, N; Ghanbari, A; Ghareghani, M; Ghavamizadeh, M; Khodadoust, S; Parishani, M; Sadeghi, H; Zibara, K, 2017) |
| "Melatonin and N-acetylserotonin (NAS) are tryptophan metabolites that have potent anti-oxidant, anti-inflammatory and neuroprotective properties in several animal models of neurological injury and disease including multiple sclerosis (MS)." | 7.83 | Efficacy of N-Acetylserotonin and Melatonin in the EAE Model of Multiple Sclerosis. ( Ariyannur, PS; Kirmani, BF; Moffett, JR; Namboodiri, AM; Ribeiro, R; Tanaka, M; Wen, J; Zhang, Y, 2016) |
| "In this study we investigated the relationship between melatonin pathway and multiple sclerosis (MS) in a high-risk Finnish population by studying the single nucleotide polymorphisms (SNPs) in the genes coding for critical enzymes and receptors involved in the melatonin pathway." | 7.78 | Melatonin pathway genes are associated with progressive subtypes and disability status in multiple sclerosis among Finnish patients. ( Einarsdottir, E; Elovaara, I; Hagman, S; Lehtimäki, T; Mononen, N; Natarajan, R; Raunio, M; Riutta, A, 2012) |
| "The association of nocturnal serum melatonin levels was investigated in acute multiple sclerosis (MS) patients with major depression (MD)." | 7.74 | The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis. ( Akpinar, Z; Gökbel, H; Okudan, N; Tokgöz, S; Uğuz, F; Yilmaz, G, 2008) |
| " In a cohort of multiple sclerosis (MS) patients ketanserin, a selective 5-HT2A receptor antagonist, induces recurrent yawning particularly when administered in daytime." | 7.69 | Bidirectional effect of electromagnetic fields on ketanserin-induced yawning in patients with multiple sclerosis: the role of melatonin. ( Sandyk, R, 1996) |
| "We have reported recently that nocturnal melatonin levels are reduced in a subgroup of patients with multiple sclerosis (MS)." | 7.69 | The relationship between melatonin secretion and serum cholesterol in patients with multiple sclerosis. ( Awerbuch, GI; Sandyk, R, 1994) |
| "Melatonin is an indole hormone secreted primarily by the pineal gland that showing anti-oxidant, anti-inflammatory and anti-apoptotic capacity." | 6.82 | Melatonin and multiple sclerosis: antioxidant, anti-inflammatory and immunomodulator mechanism of action. ( Agüera, E; Caballero-Villarraso, J; Escribano, BM; Galván, A; Muñoz-Jurado, A; Santamaría, A; Túnez, I, 2022) |
| "The pathophysiology of chronic fatigue syndrome is unknown, however activation of immune, inflammatory, oxidative and nitrosative stress mechanisms and plasma lipid peroxide elevation was reported." | 6.82 | Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone. ( Adamczyk, J; Adamczyk-Sowa, M; Misiolek, H; Niedziela, N; Owczarek, M; Sowa, P; Zwirska-Korczala, K, 2016) |
| "Melatonin is a neurohormone mainly produced by the pineal gland following a circadian rhythm." | 6.66 | The role of melatonin in Multiple Sclerosis. ( Anagnostouli, M; Skarlis, C, 2020) |
| "The prevention of neurodegenerative disorders has become an emerging public health challenge for our society." | 6.66 | Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases. ( Chen, D; Lee, TH; Zhang, T, 2020) |
| "Multiple sclerosis is an autoimmune disorder characterized by a dysregulated immune response directed against the central nervous system." | 6.53 | Anti-inflammatory effects of melatonin in multiple sclerosis. ( Calandri, IL; Correale, J; Farez, MF; Quintana, FJ, 2016) |
| "On the other hand, cerebral ischemia is a major cause of human disability all over the world." | 6.50 | The role of melatonin in multiple sclerosis, Huntington's disease and cerebral ischemia. ( Colín-González, AL; Escribano, BM; Santamaría, A; Túnez, I, 2014) |
| "Melatonin (MLT) has been reported to modulate immune system responses." | 5.62 | A comparative study of melatonin and immunomodulatory therapy with interferon beta and glatiramer acetate in a mouse model of multiple sclerosis. ( Bitzer Quintero, OK; García Martínez, DZ; Jave Suárez, LF; Leal Cortes, CA; Ortiz, GG; Ramirez Jirano, LJ; Ramos González, EJ, 2021) |
| "Multiple sclerosis is a progressive autoimmune disorder of the myelin sheath and is the most common inflammatory disease of young adults." | 5.56 | Melatonin improves memory defects in a mouse model of multiple sclerosis by up-regulating cAMP-response element-binding protein and synapse-associated proteins in the prefrontal cortex. ( AboTaleb, HA; Alghamdi, BS, 2020) |
| "Melatonin is an effective treatment in MS patients and experimental autoimmune encephalomyelitis (EAE), a mouse model of MS." | 5.48 | Spasticity Treatment Ameliorates the Efficacy of Melatonin Therapy in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model of Multiple Sclerosis. ( Farhadi, N; Ghareghani, M; Sadeghi, H; Zibara, K, 2018) |
| "Melatonin has a central role in the modulation of oxidative stress pathways." | 5.43 | Evidence for possible role of melatonin in reducing oxidative stress in multiple sclerosis through its effect on SIRT1 and antioxidant enzymes. ( Ansari, M; Askarisadr, F; Emamgholipour, S; Hossein-Nezhad, A; Sahraian, MA, 2016) |
| "Melatonin was her only treatment for the next 4 years; during this interval, her EDSS progressively recovered to 6." | 5.42 | Melatonin treatment improves primary progressive multiple sclerosis: a case report. ( Álvarez-Sánchez, N; Carrillo-Vico, A; Cruz-Chamorro, I; Guerrero, JM; Lardone, PJ; López-González, A; Martínez-López, A; Reiter, RJ, 2015) |
| "Treatment with melatonin ameliorates disease in an experimental model of multiple sclerosis and directly interferes with the differentiation of human and mouse T cells." | 5.42 | Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses. ( Balbuena Aguirre, ME; Correale, J; Farez, MF; Garo, LP; Kuchroo, VK; Mascanfroni, ID; Méndez-Huergo, SP; Murugaiyan, G; Patel, B; Quintana, FJ; Rabinovich, GA; Yeste, A; Ysrraelit, MC; Zhu, C, 2015) |
| "Melatonin is a neurohormone secreted predominantly by the pineal gland that is demonstrated to be associated with the pathogenesis of multiple sclerosis (MS)." | 5.41 | Clinical efficacy and safety of melatonin supplementation in multiple sclerosis: a systematic review. ( Gholipour-Khalili, E; Hakimzadeh, Z; Hamidi, S; Kakaei, J; Morsali, S; Naseri, A; Sabahi, Z; Sanaie, S; Talebi, M, 2023) |
| "Multiple sclerosis is a central nervous system demyelinating disease." | 5.29 | Melanin, melatonin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: a rationale for light therapy in multiple sclerosis. ( Constantinescu, CS, 1995) |
| "From the 26 patients who completed the study, there was no significant difference observed in the signs or symptoms of nocturia when taking 2 mg melatonin compared to placebo." | 5.27 | Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS). ( Canham, L; Cotterill, N; Cottrell, D; Delgado, D; Drake, MJ; Homewood, J; Inglis, K; Johnson, L; Kisanga, MC; Owen, D; White, P, 2018) |
| "This study will evaluate whether melatonin reduces the frequency of nocturia episodes in MS patients, and therefore whether 'Circadin' has the potential to reduce LUTS and fatigue, and improve cognition and overall quality of life." | 5.24 | Protocol for a randomized, double blind, placebo controlled, crossover trial of Melatonin for treatment of Nocturia in adults with Multiple Sclerosis (MeNiMS). ( Canham, L; Cotterill, N; Cottrell, D; Delgado, D; Drake, MJ; Inglis, K; Owen, D; White, P, 2017) |
| " Such pathophysiological processes include increases in oxidative and nitrosative stress, pro-inflammatory immune responses, especially T helper (Th)17 cell proliferation and activation, tryptophan catabolites, pain, fatigue and increased levels of depression." | 4.93 | Multiple Sclerosis, Gut Microbiota and Permeability: Role of Tryptophan Catabolites, Depression and the Driving Down of Local Melatonin. ( Anderson, G; Rodriguez, M; Wootla, B, 2016) |
| " The following communication is concerned with the association among MS, pregnancy, the postpartum period, and melatonin secretion and illustrates, based on a clinical case report, the influence of the pineal gland on the clinical course of MS." | 4.78 | The pineal gland and the clinical course of multiple sclerosis. ( Sandyk, R, 1992) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "Conflicting results on melatonin synthesis in multiple sclerosis (MS) have been reported due to variabilities in patient lifestyles, which are not considered when supplementing melatonin." | 4.31 | Inhibiting nighttime melatonin and boosting cortisol increase patrolling monocytes, phagocytosis, and myelination in a murine model of multiple sclerosis. ( Ghareghani, M; Laflamme, N; Pons, V; Rivest, S; Zibara, K, 2023) |
| "Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)." | 4.21 | ( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022) |
| "Melatonin (MT), a neurohormone with immunomodulatory properties, is one of the metabolites produced in the brain from tryptophan (TRP) that has already strong links with the neuropathogenesis of Multiple sclerosis (MS)." | 4.12 | Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway. ( Ejtemaei-Mehr, S; Ghahremani, MH; Ghanbari, A; Ghazi-Khansari, M; Guillemin, GJ; Jand, Y, 2022) |
| "Melatonin has been related to the pathophysiology of multiple sclerosis (MS), and its anti-inflammatory and immunomodulatory properties have been proved in numerous neurodegenerative diseases." | 4.12 | Protective effects of melatonin on changes occurring in the experimental autoimmune encephalomyelitis model of multiple sclerosis. ( Agüera, E; Caballero-Villarraso, J; Escribano, BM; Gascón, F; Giraldo, AI; Muñoz-Jurado, A; Paz-Rojas, E; Santamaría, A; Túnez, I; Valdelvira, ME, 2022) |
| "Multiple sclerosis (MS) is a progressive chronic inflammatory autoimmune disease of the myelin sheath, and melatonin is a powerful antioxidant and anti-inflammatory agent." | 3.96 | Neuroprotective Effects of Melatonin during Demyelination and Remyelination Stages in a Mouse Model of Multiple Sclerosis. ( Abo Taleb, HA; Alghamdi, BS, 2020) |
| "A growing body of evidence indicates the role of melatonin (MT) in the pathogenesis of multiple sclerosis (MS): It modulates immune function, alleviates oxidative stress and it is linked to seasonality of MS relapse." | 3.91 | Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis. ( Akgün, K; Geiger, M; Kästner, A; Kern, S; Paucke, M; Ziemssen, T, 2019) |
| " Serum levels of melatonin decrease in MS patients who are also at risk of osteoporosis." | 3.88 | Melatonin therapy reduces the risk of osteoporosis and normalizes bone formation in multiple sclerosis. ( Arnoult, D; Farhadi, N; Ghareghani, M; Scavo, L; Zibara, K, 2018) |
| "Melatonin has a beneficial role in adult rat models of multiple sclerosis (MS)." | 3.85 | Melatonin exacerbates acute experimental autoimmune encephalomyelitis by enhancing the serum levels of lactate: A potential biomarker of multiple sclerosis progression. ( Dokoohaki, S; Farhadi, N; Ghanbari, A; Ghareghani, M; Ghavamizadeh, M; Khodadoust, S; Parishani, M; Sadeghi, H; Zibara, K, 2017) |
| "Melatonin and N-acetylserotonin (NAS) are tryptophan metabolites that have potent anti-oxidant, anti-inflammatory and neuroprotective properties in several animal models of neurological injury and disease including multiple sclerosis (MS)." | 3.83 | Efficacy of N-Acetylserotonin and Melatonin in the EAE Model of Multiple Sclerosis. ( Ariyannur, PS; Kirmani, BF; Moffett, JR; Namboodiri, AM; Ribeiro, R; Tanaka, M; Wen, J; Zhang, Y, 2016) |
| " report that the circadian hormone melatonin, whose levels vary with seasonal changes in night length, shifts the immune response toward an anti-inflammatory state that may explain the seasonal variability of multiple sclerosis disease activity." | 3.81 | Melatonin Lulling Th17 Cells to Sleep. ( Cua, DJ; Lee, JS, 2015) |
| "In this study we investigated the relationship between melatonin pathway and multiple sclerosis (MS) in a high-risk Finnish population by studying the single nucleotide polymorphisms (SNPs) in the genes coding for critical enzymes and receptors involved in the melatonin pathway." | 3.78 | Melatonin pathway genes are associated with progressive subtypes and disability status in multiple sclerosis among Finnish patients. ( Einarsdottir, E; Elovaara, I; Hagman, S; Lehtimäki, T; Mononen, N; Natarajan, R; Raunio, M; Riutta, A, 2012) |
| "The association of nocturnal serum melatonin levels was investigated in acute multiple sclerosis (MS) patients with major depression (MD)." | 3.74 | The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis. ( Akpinar, Z; Gökbel, H; Okudan, N; Tokgöz, S; Uğuz, F; Yilmaz, G, 2008) |
| "In multiple sclerosis (MS), several neuroimmunomodulatory effectors are known, including melatonin." | 3.72 | The influence of immunomodulation on psycho-neuroimmunological functions in benign multiple sclerosis. ( Faustmann, PM; Haase, CG; Tinnefeld, M, 2004) |
| "We have reported recently that nocturnal melatonin levels are reduced in a subgroup of patients with multiple sclerosis (MS)." | 3.69 | The relationship between melatonin secretion and serum cholesterol in patients with multiple sclerosis. ( Awerbuch, GI; Sandyk, R, 1994) |
| " In a cohort of multiple sclerosis (MS) patients ketanserin, a selective 5-HT2A receptor antagonist, induces recurrent yawning particularly when administered in daytime." | 3.69 | Bidirectional effect of electromagnetic fields on ketanserin-induced yawning in patients with multiple sclerosis: the role of melatonin. ( Sandyk, R, 1996) |
| "Melatonin is an indole hormone secreted primarily by the pineal gland that showing anti-oxidant, anti-inflammatory and anti-apoptotic capacity." | 2.82 | Melatonin and multiple sclerosis: antioxidant, anti-inflammatory and immunomodulator mechanism of action. ( Agüera, E; Caballero-Villarraso, J; Escribano, BM; Galván, A; Muñoz-Jurado, A; Santamaría, A; Túnez, I, 2022) |
| "The pathophysiology of chronic fatigue syndrome is unknown, however activation of immune, inflammatory, oxidative and nitrosative stress mechanisms and plasma lipid peroxide elevation was reported." | 2.82 | Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone. ( Adamczyk, J; Adamczyk-Sowa, M; Misiolek, H; Niedziela, N; Owczarek, M; Sowa, P; Zwirska-Korczala, K, 2016) |
| "Melatonin was applied at a dose of 5 mg daily, one hour before sleep." | 2.75 | [Effect of melatonin on activity of superoxide dismutase (CuZn-SOD) in erythrocytes of patients during short- and long-term hypokinesis]. ( Garncarek, P; Kedziora, J; Malinowska, K; Miller, E; Mrowicka, M; Mrowicki, J; Smigielski, J, 2010) |
| "The prevention of neurodegenerative disorders has become an emerging public health challenge for our society." | 2.66 | Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases. ( Chen, D; Lee, TH; Zhang, T, 2020) |
| "Melatonin is a neurohormone mainly produced by the pineal gland following a circadian rhythm." | 2.66 | The role of melatonin in Multiple Sclerosis. ( Anagnostouli, M; Skarlis, C, 2020) |
| "Multiple sclerosis is an autoimmune disorder characterized by a dysregulated immune response directed against the central nervous system." | 2.53 | Anti-inflammatory effects of melatonin in multiple sclerosis. ( Calandri, IL; Correale, J; Farez, MF; Quintana, FJ, 2016) |
| "On the other hand, cerebral ischemia is a major cause of human disability all over the world." | 2.50 | The role of melatonin in multiple sclerosis, Huntington's disease and cerebral ischemia. ( Colín-González, AL; Escribano, BM; Santamaría, A; Túnez, I, 2014) |
| "Cataplexy is an ancillary symptom of narcolepsy and also occurs in multiple sclerosis (MS)." | 2.39 | The pineal gland, cataplexy, and multiple sclerosis. ( Sandyk, R, 1995) |
| " The aim of our study was to assess the therapeutic properties of melatonin alone or in combination with interferon β-1b (IFNβ-1b) or glatiramer acetate (GA) on EAE." | 1.72 | Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis. ( Benitez-King, G; Briones-Torres, AL; González-Ortíz, LJ; Ortíz, GG; Pacheco-Moisés, FP; Palacios-Magaña, CV, 2022) |
| "Melatonin (MLT) has been reported to modulate immune system responses." | 1.62 | A comparative study of melatonin and immunomodulatory therapy with interferon beta and glatiramer acetate in a mouse model of multiple sclerosis. ( Bitzer Quintero, OK; García Martínez, DZ; Jave Suárez, LF; Leal Cortes, CA; Ortiz, GG; Ramirez Jirano, LJ; Ramos González, EJ, 2021) |
| "Having a history of optic neuritis is associated with improved sleep quality and executive functions but increased daytime sleepiness." | 1.56 | Sleep disturbance and cognitive decline in multiple sclerosis patients with isolated optic neuritis as the first demyelinating event. ( Akbayır, E; Arsoy, E; Benbir, G; Gencer, M; Karadeniz, D; Özyurt, S; Turan, S; Türkoğlu, R; Tüzün, E; Yılmaz, V, 2020) |
| "Multiple sclerosis is a progressive autoimmune disorder of the myelin sheath and is the most common inflammatory disease of young adults." | 1.56 | Melatonin improves memory defects in a mouse model of multiple sclerosis by up-regulating cAMP-response element-binding protein and synapse-associated proteins in the prefrontal cortex. ( AboTaleb, HA; Alghamdi, BS, 2020) |
| "Melatonin is an effective treatment in MS patients and experimental autoimmune encephalomyelitis (EAE), a mouse model of MS." | 1.48 | Spasticity Treatment Ameliorates the Efficacy of Melatonin Therapy in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model of Multiple Sclerosis. ( Farhadi, N; Ghareghani, M; Sadeghi, H; Zibara, K, 2018) |
| "Melatonin has a central role in the modulation of oxidative stress pathways." | 1.43 | Evidence for possible role of melatonin in reducing oxidative stress in multiple sclerosis through its effect on SIRT1 and antioxidant enzymes. ( Ansari, M; Askarisadr, F; Emamgholipour, S; Hossein-Nezhad, A; Sahraian, MA, 2016) |
| "Treatment with melatonin ameliorates disease in an experimental model of multiple sclerosis and directly interferes with the differentiation of human and mouse T cells." | 1.42 | Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses. ( Balbuena Aguirre, ME; Correale, J; Farez, MF; Garo, LP; Kuchroo, VK; Mascanfroni, ID; Méndez-Huergo, SP; Murugaiyan, G; Patel, B; Quintana, FJ; Rabinovich, GA; Yeste, A; Ysrraelit, MC; Zhu, C, 2015) |
| "Melatonin was her only treatment for the next 4 years; during this interval, her EDSS progressively recovered to 6." | 1.42 | Melatonin treatment improves primary progressive multiple sclerosis: a case report. ( Álvarez-Sánchez, N; Carrillo-Vico, A; Cruz-Chamorro, I; Guerrero, JM; Lardone, PJ; López-González, A; Martínez-López, A; Reiter, RJ, 2015) |
| "AIS group mean score above 6 defining insomnia were observed in interferon-beta-1B-group, glatiramer acetate-group and mitoxantrone-group: 6." | 1.40 | Melatonin acts as antioxidant and improves sleep in MS patients. ( Adamczyk, J; Adamczyk-Sowa, M; Hartel, M; Mucha, S; Pierzchala, K; Sadowska-Bartosz, I; Sowa, P, 2014) |
| "Multiple sclerosis is more common in temperate latitudes, and migration studies indicate the involvement of an aetiological environmental factor in pre-pubertal life; the precise nature of this factor has never been identified and may perhaps have been overlooked." | 1.29 | Multiple sclerosis: sunlight, diet, immunology and aetiology. ( Hutter, CD; Laing, P, 1996) |
| "Currently there is no effective medical treatment for the dysarthria of MS which occurs as a result of lesions to the cerebellum and its outflow tracts." | 1.29 | Resolution of dysarthria in multiple sclerosis by treatment with weak electromagnetic fields. ( Sandyk, R, 1995) |
| "Multiple sclerosis is a central nervous system demyelinating disease." | 1.29 | Melanin, melatonin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: a rationale for light therapy in multiple sclerosis. ( Constantinescu, CS, 1995) |
| "The occurrence of migraine headaches in patients with multiple sclerosis (MS) has been recognized for quite some time but the significance of this association to the pathogenesis of MS largely has been ignored." | 1.29 | The co-occurrence of multiple sclerosis and migraine headache: the serotoninergic link. ( Awerbuch, GI; Sandyk, R, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 31 (34.07) | 18.2507 |
| 2000's | 5 (5.49) | 29.6817 |
| 2010's | 37 (40.66) | 24.3611 |
| 2020's | 18 (19.78) | 2.80 |
| Authors | Studies |
|---|---|
| Escribano, BM | 3 |
| Muñoz-Jurado, A | 2 |
| Caballero-Villarraso, J | 2 |
| Valdelvira, ME | 1 |
| Giraldo, AI | 1 |
| Paz-Rojas, E | 1 |
| Gascón, F | 1 |
| Santamaría, A | 3 |
| Agüera, E | 2 |
| Túnez, I | 3 |
| Ghareghani, M | 8 |
| Farhadi, Z | 1 |
| Rivest, S | 3 |
| Zibara, K | 8 |
| Galván, A | 1 |
| Ortíz, GG | 2 |
| Briones-Torres, AL | 1 |
| Benitez-King, G | 1 |
| González-Ortíz, LJ | 1 |
| Palacios-Magaña, CV | 1 |
| Pacheco-Moisés, FP | 1 |
| Jand, Y | 1 |
| Ghahremani, MH | 1 |
| Ghanbari, A | 3 |
| Ejtemaei-Mehr, S | 1 |
| Guillemin, GJ | 1 |
| Ghazi-Khansari, M | 1 |
| Soleimani, A | 1 |
| Ezabadi, SG | 1 |
| Möhn, N | 1 |
| Esfandabadi, ZM | 1 |
| Khosravizadeh, Z | 1 |
| Skripuletz, T | 1 |
| Azimzadeh, M | 1 |
| Pons, V | 1 |
| Laflamme, N | 1 |
| Morsali, S | 1 |
| Sabahi, Z | 1 |
| Kakaei, J | 1 |
| Hakimzadeh, Z | 1 |
| Hamidi, S | 1 |
| Gholipour-Khalili, E | 1 |
| Sanaie, S | 1 |
| Talebi, M | 1 |
| Naseri, A | 1 |
| Türkoğlu, R | 1 |
| Benbir, G | 1 |
| Özyurt, S | 1 |
| Arsoy, E | 1 |
| Akbayır, E | 1 |
| Turan, S | 1 |
| Karadeniz, D | 1 |
| Yılmaz, V | 1 |
| Gencer, M | 1 |
| Tüzün, E | 1 |
| Kern, S | 1 |
| Geiger, M | 1 |
| Paucke, M | 1 |
| Kästner, A | 1 |
| Akgün, K | 1 |
| Ziemssen, T | 1 |
| Anderson, G | 5 |
| Rodriguez, M | 4 |
| Reiter, RJ | 4 |
| Abo Taleb, HA | 1 |
| Alghamdi, BS | 2 |
| Skarlis, C | 1 |
| Anagnostouli, M | 1 |
| Yosefifard, M | 1 |
| Vaezi, G | 1 |
| Malekirad, AA | 1 |
| Faraji, F | 1 |
| Hojati, V | 1 |
| AboTaleb, HA | 1 |
| Chen, D | 1 |
| Zhang, T | 2 |
| Lee, TH | 1 |
| Nese, M | 1 |
| Riboli, G | 1 |
| Brighetti, G | 1 |
| Sassi, V | 1 |
| Camela, E | 1 |
| Caselli, G | 1 |
| Sassaroli, S | 1 |
| Borlimi, R | 1 |
| Aucoin, M | 1 |
| Cooley, K | 1 |
| Saunders, PR | 1 |
| Carè, J | 1 |
| Anheyer, D | 1 |
| Medina, DN | 1 |
| Cardozo, V | 1 |
| Remy, D | 1 |
| Hannan, N | 1 |
| Garber, A | 1 |
| Velayos, M | 1 |
| Muñoz-Serrano, AJ | 1 |
| Estefanía-Fernández, K | 1 |
| Sarmiento Caldas, MC | 1 |
| Moratilla Lapeña, L | 1 |
| López-Santamaría, M | 1 |
| López-Gutiérrez, JC | 1 |
| Li, J | 1 |
| Zhang, J | 1 |
| Shen, S | 1 |
| Zhang, B | 2 |
| Yu, WW | 1 |
| Toyoda, H | 1 |
| Huang, DQ | 1 |
| Le, MH | 1 |
| Nguyen, MH | 1 |
| Huang, R | 1 |
| Zhu, L | 1 |
| Wang, J | 6 |
| Xue, L | 1 |
| Liu, L | 2 |
| Yan, X | 2 |
| Huang, S | 1 |
| Li, Y | 6 |
| Xu, T | 1 |
| Li, C | 2 |
| Ji, F | 1 |
| Ming, F | 1 |
| Zhao, Y | 2 |
| Cheng, J | 1 |
| Wang, Y | 3 |
| Zhao, H | 1 |
| Hong, S | 1 |
| Chen, K | 2 |
| Zhao, XA | 1 |
| Zou, L | 1 |
| Sang, D | 1 |
| Shao, H | 1 |
| Guan, X | 1 |
| Chen, X | 2 |
| Chen, Y | 4 |
| Wei, J | 1 |
| Zhu, C | 2 |
| Wu, C | 1 |
| Moore, HB | 1 |
| Barrett, CD | 1 |
| Moore, EE | 1 |
| Jhunjhunwala, R | 1 |
| McIntyre, RC | 1 |
| Moore, PK | 1 |
| Hajizadeh, N | 1 |
| Talmor, DS | 1 |
| Sauaia, A | 1 |
| Yaffe, MB | 1 |
| Liu, C | 3 |
| Lin, Y | 1 |
| Dong, Y | 1 |
| Wu, Y | 1 |
| Bao, Y | 1 |
| Yan, H | 2 |
| Ma, J | 1 |
| Fernández-Cuadros, ME | 1 |
| Albaladejo-Florín, MJ | 1 |
| Álava-Rabasa, S | 1 |
| Usandizaga-Elio, I | 1 |
| Martinez-Quintanilla Jimenez, D | 1 |
| Peña-Lora, D | 1 |
| Neira-Borrajo, I | 1 |
| López-Muñoz, MJ | 1 |
| Rodríguez-de-Cía, J | 1 |
| Pérez-Moro, OS | 1 |
| Abdallah, M | 1 |
| Alsaleh, H | 1 |
| Baradwan, A | 1 |
| Alfawares, R | 1 |
| Alobaid, A | 1 |
| Rasheed, A | 1 |
| Soliman, I | 1 |
| Wendel Garcia, PD | 1 |
| Fumeaux, T | 1 |
| Guerci, P | 1 |
| Heuberger, DM | 1 |
| Montomoli, J | 2 |
| Roche-Campo, F | 1 |
| Schuepbach, RA | 1 |
| Hilty, MP | 1 |
| Poloni, TE | 1 |
| Carlos, AF | 1 |
| Cairati, M | 1 |
| Cutaia, C | 1 |
| Medici, V | 1 |
| Marelli, E | 1 |
| Ferrari, D | 1 |
| Galli, A | 1 |
| Bognetti, P | 1 |
| Davin, A | 1 |
| Cirrincione, A | 1 |
| Ceretti, A | 1 |
| Cereda, C | 1 |
| Ceroni, M | 1 |
| Tronconi, L | 1 |
| Vitali, S | 1 |
| Guaita, A | 1 |
| Leeds, JS | 1 |
| Raviprakash, V | 1 |
| Jacques, T | 1 |
| Scanlon, N | 1 |
| Cundall, J | 1 |
| Leeds, CM | 1 |
| Riva, A | 1 |
| Gray, EH | 1 |
| Azarian, S | 1 |
| Zamalloa, A | 1 |
| McPhail, MJW | 1 |
| Vincent, RP | 1 |
| Williams, R | 1 |
| Chokshi, S | 1 |
| Patel, VC | 1 |
| Edwards, LA | 1 |
| Alqarawi, W | 1 |
| Birnie, DH | 1 |
| Golian, M | 1 |
| Nair, GM | 1 |
| Nery, PB | 1 |
| Klein, A | 1 |
| Davis, DR | 1 |
| Sadek, MM | 1 |
| Neilipovitz, D | 1 |
| Johnson, CB | 1 |
| Green, MS | 1 |
| Redpath, C | 1 |
| Miller, DC | 1 |
| Beamer, P | 1 |
| Billheimer, D | 1 |
| Subbian, V | 1 |
| Sorooshian, A | 1 |
| Campbell, BS | 1 |
| Mosier, JM | 1 |
| Novaretti, JV | 1 |
| Astur, DC | 1 |
| Cavalcante, ELB | 1 |
| Kaleka, CC | 1 |
| Amaro, JT | 1 |
| Cohen, M | 1 |
| Huang, W | 1 |
| Li, T | 1 |
| Ling, Y | 1 |
| Qian, ZP | 1 |
| Zhang, YY | 1 |
| Huang, D | 1 |
| Xu, SB | 1 |
| Liu, XH | 1 |
| Xia, L | 1 |
| Yang, Y | 3 |
| Lu, SH | 1 |
| Lu, HZ | 1 |
| Zhang, R | 2 |
| Ma, JX | 1 |
| Tang, S | 1 |
| Li, CM | 1 |
| Wan, J | 1 |
| Wang, JF | 1 |
| Ma, JQ | 1 |
| Luo, JJ | 1 |
| Chen, HY | 2 |
| Mi, SL | 1 |
| Chen, SY | 1 |
| Su, YG | 1 |
| Ge, JB | 1 |
| Milheiro, SA | 1 |
| Gonçalves, J | 1 |
| Lopes, RMRM | 1 |
| Madureira, M | 1 |
| Lobo, L | 1 |
| Lopes, A | 1 |
| Nogueira, F | 1 |
| Fontinha, D | 1 |
| Prudêncio, M | 1 |
| M Piedade, MF | 1 |
| Pinto, SN | 1 |
| Florindo, PR | 1 |
| Moreira, R | 1 |
| Castillo-Lora, J | 1 |
| Delley, MF | 1 |
| Laga, SM | 1 |
| Mayer, JM | 1 |
| Sutjarit, N | 1 |
| Thongon, N | 1 |
| Weerachayaphorn, J | 1 |
| Piyachaturawat, P | 1 |
| Suksamrarn, A | 1 |
| Suksen, K | 1 |
| Papachristou, DJ | 1 |
| Blair, HC | 1 |
| Hu, Y | 1 |
| Shen, P | 1 |
| Zeng, N | 1 |
| Wang, L | 3 |
| Yan, D | 1 |
| Cui, L | 1 |
| Yang, K | 2 |
| Zhai, C | 1 |
| Yang, M | 1 |
| Lao, X | 1 |
| Sun, J | 1 |
| Ma, N | 1 |
| Wang, S | 1 |
| Ye, W | 1 |
| Guo, P | 1 |
| Rahimi, S | 1 |
| Singh, MP | 1 |
| Gupta, J | 1 |
| Nakanishi, I | 1 |
| Ohkubo, K | 1 |
| Shoji, Y | 1 |
| Fujitaka, Y | 1 |
| Shimoda, K | 1 |
| Matsumoto, KI | 1 |
| Fukuhara, K | 1 |
| Hamada, H | 1 |
| van der Boom, T | 1 |
| Gruppen, EG | 1 |
| Lefrandt, JD | 1 |
| Connelly, MA | 1 |
| Links, TP | 1 |
| Dullaart, RPF | 1 |
| Berry, JD | 1 |
| Bedlack, R | 1 |
| Mathews, D | 1 |
| Agnese, W | 1 |
| Apple, S | 1 |
| Meloncelli, S | 1 |
| Divizia, M | 1 |
| Germani, G | 1 |
| Adefegha, SA | 1 |
| Bottari, NB | 1 |
| Leal, DB | 1 |
| de Andrade, CM | 1 |
| Schetinger, MR | 1 |
| Martínez-Velasco, A | 1 |
| Perez-Ortiz, AC | 1 |
| Antonio-Aguirre, B | 1 |
| Martínez-Villaseñor, L | 1 |
| Lira-Romero, E | 1 |
| Palacio-Pastrana, C | 1 |
| Zenteno, JC | 1 |
| Ramirez, I | 1 |
| Zepeda-Palacio, C | 1 |
| Mendoza-Velásquez, C | 1 |
| Camacho-Ordóñez, A | 1 |
| Ortiz Bibriesca, DM | 1 |
| Estrada-Mena, FJ | 1 |
| Martin, BL | 1 |
| Thompson, LC | 1 |
| Kim, YH | 2 |
| Snow, SJ | 1 |
| Schladweiler, MC | 1 |
| Phillips, P | 1 |
| Harmon, M | 1 |
| King, C | 1 |
| Richards, J | 1 |
| George, I | 1 |
| Haykal-Coates, N | 1 |
| Gilmour, MI | 1 |
| Kodavanti, UP | 1 |
| Hazari, MS | 1 |
| Farraj, AK | 1 |
| Shen, Z | 1 |
| Zou, Y | 1 |
| Gao, K | 1 |
| Lazar, S | 1 |
| Wurtzel, JGT | 1 |
| Ma, P | 1 |
| Goldfinger, LE | 1 |
| Vukelic, M | 1 |
| Laloo, A | 1 |
| Kyttaris, VC | 1 |
| Chen, R | 1 |
| Chen, J | 2 |
| Xun, J | 1 |
| Hu, Z | 1 |
| Huang, Q | 2 |
| Steinhart, C | 1 |
| Shen, Y | 1 |
| Lu, H | 1 |
| Mansuri, A | 1 |
| Lokhande, K | 1 |
| Kore, S | 1 |
| Gaikwad, S | 1 |
| Nawani, N | 1 |
| Swamy, KV | 1 |
| Junnarkar, M | 1 |
| Pawar, S | 1 |
| Shaheen, MY | 1 |
| Basudan, AM | 1 |
| Niazy, AA | 1 |
| van den Beucken, JJJP | 1 |
| Jansen, JA | 1 |
| Alghamdi, HS | 1 |
| Gao, Q | 2 |
| Guo, X | 1 |
| Cao, Y | 1 |
| Jia, X | 1 |
| Xu, S | 1 |
| Lu, C | 2 |
| Zhu, H | 2 |
| Melku, M | 1 |
| Abebe, G | 1 |
| Teketel, A | 1 |
| Asrie, F | 1 |
| Yalew, A | 1 |
| Biadgo, B | 1 |
| Kassa, E | 1 |
| Damtie, D | 1 |
| Anlay, DZ | 1 |
| Ahmed, MFE | 1 |
| Ramadan, H | 1 |
| Seinige, D | 1 |
| Kehrenberg, C | 1 |
| Abd El-Wahab, A | 1 |
| Volkmann, N | 1 |
| Kemper, N | 1 |
| Schulz, J | 1 |
| Hu, MY | 1 |
| Wu, YN | 1 |
| McEvoy, MP | 1 |
| Wang, YF | 1 |
| Cong, WL | 1 |
| Liu, LP | 1 |
| Li, XX | 1 |
| Zhou, CL | 1 |
| Chen, WM | 1 |
| Wei, KL | 1 |
| Tung, SY | 1 |
| Shen, CH | 1 |
| Chang, TS | 1 |
| Yen, CW | 1 |
| Hsieh, YY | 1 |
| Chiu, WN | 1 |
| Hu, JH | 1 |
| Lu, SN | 1 |
| Hung, CH | 1 |
| Alakavuklar, MA | 1 |
| Fuqua, C | 1 |
| Luo, KL | 1 |
| Underwood, RS | 1 |
| Greenwald, I | 1 |
| Elashiry, MM | 1 |
| Elashiry, M | 1 |
| Zeitoun, R | 1 |
| Elsayed, R | 1 |
| Tian, F | 1 |
| Saber, SE | 1 |
| Elashry, SH | 1 |
| Tay, FR | 1 |
| Cutler, CW | 1 |
| O'Dowd, A | 1 |
| Maciel, M | 1 |
| Poole, ST | 1 |
| Jobling, MG | 1 |
| Rollenhagen, JE | 1 |
| Woods, CM | 1 |
| Sincock, SA | 1 |
| McVeigh, AL | 1 |
| Gregory, MJ | 1 |
| Maves, RC | 1 |
| Prouty, MG | 1 |
| Holmes, RK | 1 |
| Savarino, SJ | 1 |
| Mor, MK | 1 |
| Palevsky, PM | 1 |
| Kaufman, JS | 1 |
| Thiessen Philbrook, H | 1 |
| Weisbord, SD | 1 |
| Parikh, CR | 1 |
| John, CM | 1 |
| Phillips, NJ | 1 |
| Jarvis, GA | 1 |
| Zhu, Y | 1 |
| Kilburn, S | 1 |
| Kapoor, M | 1 |
| Chaturvedi, S | 1 |
| Shaw, KJ | 1 |
| Chaturvedi, V | 1 |
| Kong, X | 1 |
| Xiao, H | 1 |
| Feng, X | 1 |
| Tu, H | 1 |
| Feng, J | 1 |
| Sabet, M | 1 |
| Tarazi, Z | 1 |
| Griffith, DC | 1 |
| Nguyen, F | 1 |
| Guan, P | 1 |
| Guerrero, DT | 1 |
| Kolla, V | 1 |
| Naraparaju, K | 1 |
| Perry, LM | 1 |
| Soberman, D | 1 |
| Pressly, BB | 1 |
| Alferiev, IS | 1 |
| Chorny, M | 1 |
| Brodeur, GM | 1 |
| Gao, X | 2 |
| Cheng, YH | 1 |
| Enten, GA | 1 |
| DeSantis, AJ | 1 |
| Gaponenko, V | 1 |
| Majetschak, M | 1 |
| Kim, DY | 1 |
| Choi, MJ | 1 |
| Ko, TK | 1 |
| Lee, NH | 1 |
| Kim, OH | 1 |
| Cheon, HG | 1 |
| Cai, H | 1 |
| Yip, V | 1 |
| Lee, MV | 1 |
| Wong, S | 1 |
| Saad, O | 1 |
| Ma, S | 1 |
| Ljumanovic, N | 1 |
| Khojasteh, SC | 1 |
| Kamath, AV | 1 |
| Shen, BQ | 1 |
| Cuypers, ML | 1 |
| Chanteux, H | 1 |
| Gillent, E | 1 |
| Bonnaillie, P | 1 |
| Saunders, K | 1 |
| Beckers, C | 1 |
| Delatour, C | 1 |
| Dell'Aiera, S | 1 |
| Ungell, AL | 1 |
| Nicolaï, J | 1 |
| Knapp, AK | 1 |
| Chen, A | 1 |
| Griffin-Nolan, RJ | 1 |
| Baur, LE | 1 |
| Carroll, CJW | 1 |
| Gray, JE | 1 |
| Hoffman, AM | 1 |
| Li, X | 4 |
| Post, AK | 1 |
| Slette, IJ | 1 |
| Collins, SL | 1 |
| Luo, Y | 1 |
| Smith, MD | 1 |
| Temitayo, GI | 1 |
| Olawande, B | 1 |
| Emmanuel, YO | 1 |
| Timothy, AT | 1 |
| Kehinde, O | 1 |
| Susan, LF | 1 |
| Ezra, L | 1 |
| Joseph, OO | 1 |
| Lev, S | 1 |
| Desmarini, D | 1 |
| Liuwantara, D | 1 |
| Sorrell, TC | 1 |
| Hawthorne, WJ | 1 |
| Djordjevic, JT | 1 |
| Verso, MG | 1 |
| Costantino, C | 1 |
| Marrella, A | 1 |
| Immordino, P | 1 |
| Vitale, F | 1 |
| Amodio, E | 1 |
| Wang, YD | 1 |
| Yao, WL | 1 |
| Xin, ZM | 1 |
| Han, TT | 1 |
| Wang, ZG | 1 |
| Chen, L | 1 |
| Cai, C | 1 |
| Zhang, Y | 5 |
| Ba, D | 1 |
| Wen, S | 1 |
| Tian, Q | 1 |
| Lv, W | 1 |
| Cheng, G | 1 |
| Li, N | 1 |
| Yue, XY | 1 |
| Chu, WJ | 1 |
| Chen, Q | 1 |
| Choi, ES | 1 |
| Zhao, X | 3 |
| Zhou, HD | 1 |
| Sun, XF | 1 |
| Sharma, S | 2 |
| Chhoker, S | 1 |
| Xie, C | 1 |
| Ong, EWY | 1 |
| Tan, ZK | 1 |
| Evans, S | 1 |
| Weinheimer, CJ | 1 |
| Kovacs, A | 1 |
| Williams, JW | 1 |
| Randolph, GJ | 1 |
| Jiang, W | 1 |
| Barger, PM | 1 |
| Mann, DL | 1 |
| Liu, J | 2 |
| Huang, Y | 1 |
| Kong, L | 1 |
| Yu, X | 1 |
| Feng, B | 1 |
| Liu, D | 1 |
| Zhao, B | 1 |
| Mendes, GC | 1 |
| Yuan, P | 1 |
| Ge, D | 1 |
| Wang, WM | 1 |
| Fontes, EPB | 1 |
| Li, P | 1 |
| Shan, L | 1 |
| He, P | 1 |
| Katoh, T | 1 |
| Sengoku, T | 1 |
| Hirata, K | 1 |
| Ogata, K | 1 |
| Suga, H | 1 |
| Shun, C | 1 |
| Yong-Yi, J | 1 |
| Mei-Li, C | 1 |
| Shi-Li, L | 1 |
| Jian-Bo, Z | 1 |
| Dan-Li, W | 1 |
| Zhi-Min, G | 1 |
| Ibrahim, AM | 1 |
| Zakhary, SY | 1 |
| Amin, SAW | 1 |
| Ugurlu, M | 1 |
| Fornari, VJ | 1 |
| Hartmann, MSM | 1 |
| Vanni, JR | 1 |
| Rodriguez, R | 1 |
| Langaro, MC | 1 |
| Pelepenko, LE | 1 |
| Zaia, AA | 1 |
| Nakanjako, D | 1 |
| Zalwango, F | 1 |
| Wairagala, P | 1 |
| Luboga, F | 1 |
| Andia Biraro, I | 1 |
| Bukirwa, VD | 1 |
| Mboowa, MG | 1 |
| Cose, S | 1 |
| Seeley, J | 1 |
| Elliott, A | 1 |
| Zhao, G | 1 |
| Sun, P | 1 |
| Hao, S | 1 |
| Wang, X | 1 |
| Qu, G | 1 |
| Xing, Y | 1 |
| Xu, X | 1 |
| Maierhofer, M | 1 |
| Rieger, V | 1 |
| Mayr, T | 1 |
| Liu, Y | 2 |
| Zhang, Q | 1 |
| Bigliardi, AP | 1 |
| Fernandes, CLF | 1 |
| Pinto, EA | 1 |
| Dos Santos, M | 1 |
| Garcia, EM | 1 |
| Baisch, PRM | 1 |
| Soares, MCF | 1 |
| Muccillo-Baisch, AL | 1 |
| da Silva Júnior, FMR | 1 |
| Yu, W | 1 |
| Ju, C | 1 |
| Wang, K | 1 |
| Zheng, Z | 1 |
| Liu, H | 1 |
| Gao, Y | 1 |
| Martínez-Navarro, EM | 1 |
| Cebrián-Tarancón, C | 1 |
| Moratalla-López, N | 1 |
| Lorenzo, C | 1 |
| Alonso, GL | 1 |
| Salinas, RM | 1 |
| Bermúdez de Castro, JM | 1 |
| Modesto-Mata, M | 1 |
| Martín-Francés, L | 1 |
| García-Campos, C | 1 |
| Martínez de Pinillos, M | 1 |
| Martinón-Torres, M | 1 |
| Hasani, M | 1 |
| Wu, F | 2 |
| Warriner, K | 1 |
| Kurz, M | 1 |
| Gretzke, D | 1 |
| Hörlein, R | 1 |
| Turpault, S | 1 |
| Atzrodt, J | 1 |
| Derdau, V | 1 |
| Yao, Y | 1 |
| Ou, X | 1 |
| Zhao, S | 1 |
| Tian, B | 1 |
| Jin, S | 1 |
| Jiang, Z | 1 |
| Zhou, Z | 1 |
| Liu, M | 2 |
| Jiang, GD | 1 |
| Mou, LH | 1 |
| Chen, JJ | 1 |
| Li, ZY | 1 |
| He, SG | 1 |
| Reale, E | 1 |
| Fustinoni, S | 1 |
| Mercadante, R | 1 |
| Polledri, E | 1 |
| Hopf, NB | 1 |
| Grant, PC | 1 |
| Levy, K | 1 |
| Lattimer, TA | 1 |
| Depner, RM | 1 |
| Kerr, CW | 1 |
| Sato, J | 1 |
| Merenda, MEZ | 1 |
| Uemoto, AT | 1 |
| Dos Santos, MP | 1 |
| Barion, MRL | 1 |
| Carciofi, AC | 1 |
| de Paula Dorigam, JC | 1 |
| Ribeiro, LB | 1 |
| Vasconcellos, RS | 1 |
| Waller, SB | 1 |
| Peter, CM | 1 |
| Hoffmann, JF | 1 |
| Cleff, MB | 1 |
| Faria de, RO | 1 |
| Zani, JL | 1 |
| Martins, BA | 1 |
| Sande, D | 1 |
| Solares, MD | 1 |
| Takahashi, JA | 1 |
| Yang, S | 2 |
| Jia, Y | 1 |
| Yin, C | 1 |
| Zhao, R | 1 |
| Ojha, M | 1 |
| Wu, B | 1 |
| Deepa, M | 1 |
| Mo, J | 1 |
| Au, DW | 1 |
| Wan, MT | 1 |
| Shi, J | 1 |
| Zhang, G | 1 |
| Winkler, C | 1 |
| Kong, RY | 1 |
| Seemann, F | 1 |
| Bianco, M | 1 |
| Calvano, CD | 1 |
| Ventura, G | 1 |
| Bianco, G | 1 |
| Losito, I | 1 |
| Cataldi, TRI | 1 |
| Angiolella, L | 1 |
| Staudt, A | 1 |
| Duarte, PF | 1 |
| Amaral, BPD | 1 |
| Peixoto Andrade, BCO | 1 |
| Simas, NK | 1 |
| Correa Ramos Leal, I | 1 |
| Sangenito, LS | 1 |
| Santos, ALSD | 1 |
| de Oliveira, D | 1 |
| Junges, A | 1 |
| Cansian, RL | 1 |
| Paroul, N | 1 |
| Siu, J | 1 |
| Klingler, L | 1 |
| Hung, CT | 1 |
| Jeong, SH | 1 |
| Smith, S | 1 |
| Tingle, MD | 1 |
| Wagner Mackenzie, B | 1 |
| Biswas, K | 1 |
| Douglas, RG | 1 |
| Oza, AM | 1 |
| Lorusso, D | 1 |
| Aghajanian, C | 1 |
| Oaknin, A | 1 |
| Dean, A | 1 |
| Colombo, N | 1 |
| Weberpals, JI | 1 |
| Clamp, AR | 1 |
| Scambia, G | 1 |
| Leary, A | 1 |
| Holloway, RW | 1 |
| Gancedo, MA | 1 |
| Fong, PC | 1 |
| Goh, JC | 1 |
| O'Malley, DM | 1 |
| Armstrong, DK | 1 |
| Banerjee, S | 1 |
| García-Donas, J | 1 |
| Swisher, EM | 1 |
| Cella, D | 1 |
| Meunier, J | 1 |
| Goble, S | 1 |
| Cameron, T | 1 |
| Maloney, L | 1 |
| Mörk, AC | 1 |
| Bedel, J | 1 |
| Ledermann, JA | 1 |
| Coleman, RL | 1 |
| Vlek, SL | 1 |
| Burm, R | 1 |
| Govers, TM | 1 |
| Vleugels, MPH | 1 |
| Tuynman, JB | 1 |
| Mijatovic, V | 1 |
| Leicht, AS | 1 |
| Connor, J | 1 |
| Conduit, N | 1 |
| Vaquera, A | 1 |
| Gómez, MA | 1 |
| McKay, JA | 1 |
| Church, AL | 1 |
| Rubin, N | 1 |
| Emory, TH | 1 |
| Hoven, NF | 1 |
| Kuehn-Hajder, JE | 1 |
| Nelson, MT | 1 |
| Ramanna, S | 1 |
| Auerbach, EJ | 1 |
| Moeller, S | 1 |
| Bolan, PJ | 1 |
| Fox, NP | 1 |
| Leonard, M | 1 |
| Sjerps, MJ | 1 |
| Chang, EF | 1 |
| Hyun, S | 1 |
| Saejio, A | 1 |
| Shanmugam, S | 1 |
| Liu, X | 1 |
| Sun, M | 1 |
| Bai, Z | 1 |
| Jaque-Fernandez, F | 1 |
| Beaulant, A | 1 |
| Berthier, C | 1 |
| Monteiro, L | 1 |
| Allard, B | 1 |
| Casas, M | 1 |
| Rieusset, J | 1 |
| Jacquemond, V | 1 |
| Góngora-García, OR | 1 |
| Aca-Aca, G | 1 |
| Baz-Rodríguez, SA | 1 |
| Monte, A | 1 |
| Maganaris, C | 1 |
| Baltzopoulos, V | 1 |
| Zamparo, P | 1 |
| Wang, Z | 2 |
| Hou, Y | 1 |
| Cai, L | 1 |
| Tu, YJ | 1 |
| Tan, B | 1 |
| Jiang, L | 1 |
| Wu, ZH | 1 |
| Yu, HJ | 1 |
| Li, XQ | 1 |
| Yang, AD | 1 |
| Titze, IR | 1 |
| Palaparthi, A | 1 |
| Mau, T | 1 |
| González, MA | 1 |
| Goiri, F | 1 |
| Barandika, JF | 1 |
| García-Pérez, AL | 1 |
| Jatt, LP | 1 |
| Gandhi, MM | 1 |
| Guo, R | 1 |
| Sukhija-Cohen, A | 1 |
| Bhattacharya, D | 1 |
| Tseng, CH | 1 |
| Chew, KW | 1 |
| Onwumere, J | 1 |
| Pia Tek, J | 1 |
| Budnyak, T | 1 |
| Budnyk, S | 1 |
| Karim, Z | 1 |
| Thersleff, T | 1 |
| Kuśtrowski, P | 1 |
| Mathew, AP | 1 |
| Slabon, A | 1 |
| Guo, M | 1 |
| Zhao, T | 1 |
| Xing, Z | 1 |
| Qiu, Y | 1 |
| Pan, K | 1 |
| Li, Z | 2 |
| Zhou, W | 1 |
| Ghassemi Tabrizi, S | 1 |
| Arbuznikov, AV | 1 |
| Jiménez-Hoyos, CA | 1 |
| Kaupp, M | 1 |
| Lin, MH | 2 |
| Bulman, DM | 1 |
| Remucal, CK | 1 |
| Chaplin, BP | 1 |
| Laguerre, A | 1 |
| George, LA | 1 |
| Gall, ET | 1 |
| Emerson, MS | 1 |
| Wang, H | 3 |
| Maginn, EJ | 1 |
| Margulis, CJ | 1 |
| Li, H | 2 |
| Feng, W | 1 |
| Kang, X | 2 |
| Yan, S | 1 |
| Chao, M | 1 |
| Mo, S | 1 |
| Sun, W | 1 |
| Lu, Y | 1 |
| Chen, C | 1 |
| Stevens, DM | 1 |
| Adiseshaiah, P | 1 |
| Dasa, SSK | 1 |
| Potter, TM | 1 |
| Skoczen, SL | 1 |
| Snapp, KS | 1 |
| Cedrone, E | 1 |
| Patel, N | 1 |
| Busman-Sahay, K | 1 |
| Rosen, EP | 1 |
| Sykes, C | 1 |
| Cottrell, M | 1 |
| Dobrovolskaia, MA | 1 |
| Estes, JD | 1 |
| Kashuba, ADM | 1 |
| Stern, ST | 1 |
| Özütemiz, C | 1 |
| Neil, EC | 1 |
| Tanwar, M | 1 |
| Rubin, NT | 1 |
| Ozturk, K | 1 |
| Cayci, Z | 1 |
| Duscha, BD | 1 |
| Kraus, WE | 1 |
| Jones, WS | 1 |
| Robbins, JL | 1 |
| Piner, LW | 1 |
| Huffman, KM | 1 |
| Allen, JD | 1 |
| Annex, BH | 1 |
| Mehmood, T | 1 |
| Ahmad, I | 1 |
| Bibi, S | 1 |
| Mustafa, B | 1 |
| Ali, I | 1 |
| Dahal, RH | 1 |
| Chaudhary, DK | 1 |
| Kim, DU | 1 |
| Kim, J | 1 |
| Yeter, HH | 1 |
| Gonul, I | 1 |
| Guz, G | 1 |
| Helvaci, O | 1 |
| Korucu, B | 1 |
| Akcay, OF | 1 |
| Derici, U | 1 |
| Arinsoy, T | 1 |
| Neffati, R | 1 |
| Judeinstein, P | 1 |
| Rault, J | 1 |
| Xu, Y | 1 |
| Chai, X | 1 |
| Ren, T | 1 |
| Yu, S | 1 |
| Fu, Q | 2 |
| Ye, J | 1 |
| Ge, X | 1 |
| Song, J | 1 |
| Yang, H | 2 |
| El-Baba, TJ | 1 |
| Lutomski, CA | 1 |
| Kantsadi, AL | 1 |
| Malla, TR | 1 |
| John, T | 1 |
| Mikhailov, V | 1 |
| Bolla, JR | 1 |
| Schofield, CJ | 1 |
| Zitzmann, N | 1 |
| Vakonakis, I | 1 |
| Robinson, CV | 1 |
| Langham, MC | 1 |
| Caporale, AS | 1 |
| Wehrli, FW | 1 |
| Parry, S | 1 |
| Schwartz, N | 1 |
| den Boer, RB | 1 |
| Jones, KI | 1 |
| Ash, S | 1 |
| van Boxel, GI | 1 |
| Gillies, RS | 1 |
| O'Donnell, T | 1 |
| Ruurda, JP | 1 |
| Sgromo, B | 1 |
| Silva, MA | 1 |
| Maynard, ND | 1 |
| Sivieri, EM | 1 |
| Eichenwald, EC | 1 |
| Rub, D | 1 |
| Abbasi, S | 1 |
| Krahnert, I | 1 |
| Bolze, A | 1 |
| Gibon, Y | 1 |
| Fernie, AR | 1 |
| Huang, L | 1 |
| Wan, Y | 1 |
| Dang, Z | 1 |
| Yang, P | 1 |
| Yang, Q | 1 |
| Wu, S | 2 |
| Lin, CC | 1 |
| Hsu, CT | 1 |
| Liu, W | 2 |
| Huang, SC | 1 |
| Kortz, U | 1 |
| Mougharbel, AS | 1 |
| Chen, TY | 1 |
| Hu, CW | 1 |
| Lee, JF | 1 |
| Wang, CC | 1 |
| Liao, YF | 1 |
| Li, LJ | 1 |
| Li, L | 1 |
| Peng, S | 1 |
| Stimming, U | 1 |
| Hebbar Kannur, K | 1 |
| Yaqub, TB | 1 |
| Pupier, C | 1 |
| Héau, C | 1 |
| Cavaleiro, A | 1 |
| Yamamoto, S | 1 |
| Ono, A | 1 |
| Matsui, J | 1 |
| Hoshino, N | 1 |
| Akutagawa, T | 1 |
| Miyashita, T | 1 |
| Mitsuishi, M | 1 |
| Patel, SM | 1 |
| Smith, TG | 1 |
| Morton, M | 1 |
| Stiers, KM | 1 |
| Seravalli, J | 1 |
| Mayclin, SJ | 1 |
| Edwards, TE | 1 |
| Tanner, JJ | 1 |
| Becker, DF | 1 |
| Butcher, TW | 1 |
| Yang, JL | 1 |
| Hartwig, JF | 1 |
| Yu, MF | 1 |
| Xia, ZZ | 1 |
| Yao, JC | 1 |
| Feng, Z | 1 |
| Li, DH | 1 |
| Liu, T | 1 |
| Cheng, GJ | 1 |
| He, DL | 1 |
| Li, XH | 1 |
| Huurman, R | 1 |
| Schinkel, AFL | 1 |
| de Jong, PL | 1 |
| van Slegtenhorst, MA | 1 |
| Hirsch, A | 1 |
| Michels, M | 1 |
| Kataja, A | 1 |
| Tarvasmäki, T | 1 |
| Lassus, J | 1 |
| Sionis, A | 1 |
| Mebazaa, A | 1 |
| Pulkki, K | 1 |
| Banaszewski, M | 1 |
| Carubelli, V | 1 |
| Hongisto, M | 1 |
| Jankowska, E | 1 |
| Jurkko, R | 1 |
| Jäntti, T | 1 |
| Kasztura, M | 1 |
| Parissis, J | 1 |
| Sabell, T | 1 |
| Silva-Cardoso, J | 1 |
| Spinar, J | 1 |
| Tolppanen, H | 1 |
| Harjola, VP | 1 |
| Carsetti, A | 1 |
| Damiani, E | 1 |
| Casarotta, E | 1 |
| Scorcella, C | 1 |
| Domizi, R | 1 |
| Gasparri, F | 1 |
| Gabbanelli, V | 1 |
| Pantanetti, S | 1 |
| Carozza, R | 1 |
| Adrario, E | 1 |
| Donati, A | 1 |
| Almada, E | 1 |
| Pariani, A | 1 |
| Rivabella Maknis, T | 1 |
| Hidalgo, F | 1 |
| Vena, R | 1 |
| Favre, C | 1 |
| Larocca, MC | 1 |
| Lu, ZY | 1 |
| Jiang, WD | 1 |
| Wu, P | 1 |
| Kuang, SY | 1 |
| Tang, L | 1 |
| Yang, J | 1 |
| Zhou, XQ | 1 |
| Feng, L | 1 |
| Leal, M | 1 |
| Zampini, IC | 1 |
| Mercado, MI | 1 |
| Moreno, MA | 1 |
| Simirgiotis, MJ | 1 |
| Bórquez, J | 1 |
| Ponessa, G | 1 |
| Isla, MI | 1 |
| Saliu, IO | 1 |
| Amoo, ZA | 1 |
| Khan, MF | 1 |
| Olaleye, MT | 1 |
| Rema, V | 1 |
| Akinmoladun, AC | 1 |
| Khan, AU | 1 |
| Rahman, AU | 1 |
| Yuan, Q | 1 |
| Ahmad, A | 1 |
| Khan, ZUH | 1 |
| Mahnashi, MH | 1 |
| Alyami, BA | 1 |
| Alqahtani, YS | 1 |
| Ullah, S | 1 |
| Wirman, AP | 1 |
| Gao, M | 1 |
| Deng, L | 1 |
| Zhang, K | 1 |
| Wang, M | 1 |
| Xia, Z | 1 |
| Gao, D | 1 |
| Balkissou, AD | 1 |
| Poka-Mayap, V | 1 |
| Massongo, M | 1 |
| Djenabou, A | 1 |
| Endale-Mangamba, LM | 1 |
| Olomo, EJ | 1 |
| Boulleys-Nana, JR | 1 |
| Diffo-Sonkoue, L | 1 |
| Adidigue-Ndiome, R | 1 |
| Alexandra, AJE | 1 |
| Haman-Wabi, AB | 1 |
| Adama, S | 1 |
| Iddi-Faical, A | 1 |
| Pefura-Yone, EW | 1 |
| Zhao, Q | 1 |
| Tong, W | 1 |
| Ge, C | 1 |
| Zhao, D | 1 |
| Norbäck, D | 1 |
| Li, B | 1 |
| Zhao, Z | 1 |
| Huang, C | 1 |
| Zhang, X | 1 |
| Qian, H | 1 |
| Yang, X | 1 |
| Sun, Y | 1 |
| Sundell, J | 1 |
| Deng, Q | 1 |
| Kim, HJ | 1 |
| Jeon, JW | 1 |
| Hwang, SM | 1 |
| Chu, KI | 1 |
| Cha, YH | 1 |
| Kwak, YD | 1 |
| Choi, SD | 1 |
| Aslam, M | 1 |
| Kim, CG | 1 |
| Zhou, J | 1 |
| Yang, E | 1 |
| Yang, W | 1 |
| Hawkes, CH | 1 |
| Baker, MD | 1 |
| Pohl, D | 1 |
| Lechner-Scott, J | 1 |
| Levy, M | 1 |
| Giovannoni, G | 1 |
| Delgado, D | 2 |
| Canham, L | 2 |
| Cotterill, N | 2 |
| Cottrell, D | 2 |
| Drake, MJ | 2 |
| Inglis, K | 2 |
| Owen, D | 2 |
| White, P | 2 |
| Dokoohaki, S | 2 |
| Farhadi, N | 5 |
| Sadeghi, H | 3 |
| Adamczyk-Sowa, M | 5 |
| Galiniak, S | 1 |
| Żyracka, E | 1 |
| Grzesik, M | 1 |
| Naparło, K | 1 |
| Sowa, P | 5 |
| Bartosz, G | 1 |
| Sadowska-Bartosz, I | 2 |
| Scavo, L | 1 |
| Arnoult, D | 1 |
| Ramos González, EJ | 1 |
| Ramirez Jirano, LJ | 1 |
| García Martínez, DZ | 1 |
| Jave Suárez, LF | 1 |
| Leal Cortes, CA | 1 |
| Bitzer Quintero, OK | 1 |
| Homewood, J | 1 |
| Johnson, L | 1 |
| Kisanga, MC | 1 |
| Yeganeh Salehpour, M | 1 |
| Mollica, A | 1 |
| Momtaz, S | 1 |
| Sanadgol, N | 1 |
| Farzaei, MH | 1 |
| Barun, B | 1 |
| Kashani, IR | 1 |
| Rajabi, Z | 1 |
| Akbari, M | 1 |
| Hassanzadeh, G | 1 |
| Mohseni, A | 1 |
| Eramsadati, MK | 1 |
| Rafiee, K | 1 |
| Beyer, C | 1 |
| Kipp, M | 1 |
| Zendedel, A | 1 |
| Pierzchala, K | 2 |
| Mucha, S | 2 |
| Adamczyk, J | 2 |
| Hartel, M | 2 |
| Colín-González, AL | 1 |
| Polaniak, R | 1 |
| Kukla, M | 1 |
| López-González, A | 1 |
| Álvarez-Sánchez, N | 1 |
| Lardone, PJ | 1 |
| Cruz-Chamorro, I | 1 |
| Martínez-López, A | 1 |
| Guerrero, JM | 1 |
| Carrillo-Vico, A | 1 |
| Damasceno, A | 1 |
| Moraes, AS | 1 |
| Farias, A | 1 |
| Damasceno, BP | 1 |
| dos Santos, LM | 1 |
| Cendes, F | 1 |
| Lee, JS | 1 |
| Cua, DJ | 1 |
| Farez, MF | 2 |
| Mascanfroni, ID | 1 |
| Méndez-Huergo, SP | 1 |
| Yeste, A | 1 |
| Murugaiyan, G | 1 |
| Garo, LP | 1 |
| Balbuena Aguirre, ME | 1 |
| Patel, B | 1 |
| Ysrraelit, MC | 1 |
| Kuchroo, VK | 1 |
| Rabinovich, GA | 1 |
| Quintana, FJ | 2 |
| Correale, J | 2 |
| Emamgholipour, S | 1 |
| Hossein-Nezhad, A | 1 |
| Sahraian, MA | 1 |
| Askarisadr, F | 1 |
| Ansari, M | 1 |
| Chen, SJ | 1 |
| Huang, SH | 1 |
| Chen, JW | 1 |
| Wang, KC | 1 |
| Yang, YR | 1 |
| Liu, PF | 1 |
| Lin, GJ | 1 |
| Sytwu, HK | 1 |
| Niedziela, N | 1 |
| Misiolek, H | 1 |
| Owczarek, M | 2 |
| Zwirska-Korczala, K | 1 |
| Zostawa, J | 1 |
| Mazur, B | 1 |
| Pierzchała, K | 1 |
| Kuklina, EM | 1 |
| Calandri, IL | 1 |
| Wen, J | 1 |
| Ariyannur, PS | 1 |
| Ribeiro, R | 1 |
| Tanaka, M | 1 |
| Moffett, JR | 1 |
| Kirmani, BF | 1 |
| Namboodiri, AM | 1 |
| Wootla, B | 1 |
| Khodadoust, S | 1 |
| Parishani, M | 1 |
| Ghavamizadeh, M | 1 |
| Gong, X | 1 |
| Xie, Z | 1 |
| Zuo, H | 1 |
| Akpinar, Z | 1 |
| Tokgöz, S | 1 |
| Gökbel, H | 1 |
| Okudan, N | 1 |
| Uğuz, F | 1 |
| Yilmaz, G | 1 |
| Mrowicka, M | 2 |
| Garncarek, P | 1 |
| Miller, E | 2 |
| Kedziora, J | 2 |
| Smigielski, J | 1 |
| Malinowska, K | 2 |
| Mrowicki, J | 1 |
| Schreuder, F | 1 |
| Deretzi, G | 1 |
| Kountouras, J | 1 |
| Gavalas, E | 1 |
| Polyzos, SA | 1 |
| Zavos, C | 1 |
| Klonizakis, P | 1 |
| Vardaka, E | 1 |
| Skendros, P | 1 |
| Katsinelos, P | 1 |
| Giartza-Taxidou, E | 1 |
| Kyriakou, P | 1 |
| Majsterek, I | 1 |
| Natarajan, R | 1 |
| Einarsdottir, E | 1 |
| Riutta, A | 1 |
| Hagman, S | 1 |
| Raunio, M | 1 |
| Mononen, N | 1 |
| Lehtimäki, T | 1 |
| Elovaara, I | 1 |
| Haase, CG | 1 |
| Tinnefeld, M | 1 |
| Faustmann, PM | 1 |
| Persinger, MA | 1 |
| Tan, DX | 1 |
| Manchester, LC | 1 |
| Tamura, H | 1 |
| Sandyk, R | 27 |
| Dann, LC | 1 |
| Iacono, RP | 2 |
| Awerbuch, GI | 6 |
| Hutter, CD | 1 |
| Laing, P | 1 |
| Constantinescu, CS | 1 |
| Olson, RC | 1 |
| Lindstedt, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluating the Potential Role of Melatonin in Subjects With Relapsing Multiple Sclerosis (MS)[NCT03498131] | Early Phase 1 | 30 participants (Actual) | Interventional | 2018-05-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
29 reviews available for melatonin and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Melatonin and multiple sclerosis: antioxidant, anti-inflammatory and immunomodulator mechanism of action.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents; Antioxidants; Catalase; COVID-19; Estrogens; Femal | 2022 |
Influence of hormones in multiple sclerosis: focus on the most important hormones.
Topics: Gonadal Steroid Hormones; Humans; Melatonin; Multiple Sclerosis; Neuroprotective Agents; Oxidative S | 2023 |
Melatonin and vitamin D, two sides of the same coin, better to land on its edge to improve multiple sclerosis.
Topics: Humans; Melatonin; Multiple Sclerosis; Vitamin D; Vitamin D Deficiency; Vitamins | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Clinical efficacy and safety of melatonin supplementation in multiple sclerosis: a systematic review.
Topics: Dietary Supplements; Humans; Melatonin; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; | 2023 |
Multiple Sclerosis: Melatonin, Orexin, and Ceramide Interact with Platelet Activation Coagulation Factors and Gut-Microbiome-Derived Butyrate in the Circadian Dysregulation of Mitochondria in Glia and Immune Cells.
Topics: Animals; Butyrates; Ceramides; Chronobiology Disorders; Gastrointestinal Microbiome; Humans; Immunit | 2019 |
The role of melatonin in Multiple Sclerosis.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Humans; Melatonin; Multiple Sclerosis; Neurotr | 2020 |
Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Circadian Rhythm; Dementia, Vascular; Hum | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
Latitude, Vitamin D, Melatonin, and Gut Microbiota Act in Concert to Initiate Multiple Sclerosis: A New Mechanistic Pathway.
Topics: Animals; Endotoxins; Gastrointestinal Microbiome; Geography, Medical; Humans; Melatonin; Multiple Sc | 2018 |
Melatonin and Multiple Sclerosis: From Plausible Neuropharmacological Mechanisms of Action to Experimental and Clinical Evidence.
Topics: Administration, Oral; Animals; Biological Availability; Female; Humans; Melatonin; Mice; Multiple Sc | 2019 |
Pathophysiological background and clinical characteristics of sleep disorders in multiple sclerosis.
Topics: Animals; Fatigue; Humans; Melatonin; Multiple Sclerosis; Narcolepsy; Restless Legs Syndrome; Sleep W | 2013 |
The role of melatonin in multiple sclerosis, Huntington's disease and cerebral ischemia.
Topics: Brain Ischemia; Disease Progression; Humans; Huntington Disease; Melatonin; Multiple Sclerosis | 2014 |
Multiple sclerosis: the role of melatonin and N-acetylserotonin.
Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; | 2015 |
[Melatonin as an inducing factor for multiple sclerosis].
Topics: Humans; Immunomodulation; Interleukin-17; Melatonin; Multiple Sclerosis; Neurodegenerative Diseases; | 2016 |
Anti-inflammatory effects of melatonin in multiple sclerosis.
Topics: Animals; Anti-Inflammatory Agents; Humans; Immune System; Melatonin; Multiple Sclerosis | 2016 |
Multiple Sclerosis, Gut Microbiota and Permeability: Role of Tryptophan Catabolites, Depression and the Driving Down of Local Melatonin.
Topics: Animals; Depression; Gastrointestinal Microbiome; Humans; Melatonin; Multiple Sclerosis; Permeabilit | 2016 |
Multiple sclerosis, seizures, and antiepileptics: role of IL-18, IDO, and melatonin.
Topics: Anticonvulsants; Comorbidity; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon-gamma; Interl | 2011 |
Melatonin defeats neurally-derived free radicals and reduces the associated neuromorphological and neurobehavioral damage.
Topics: Animals; Antioxidants; Free Radical Scavengers; Free Radicals; Head Injuries, Closed; Humans; Melato | 2007 |
Chronic relapsing multiple sclerosis: a case of rapid recovery by application of weak electromagnetic fields.
Topics: Antineoplastic Agents; Brain; Demyelinating Diseases; Electromagnetic Fields; Female; Humans; Interf | 1995 |
Resolution of Lhermitte's sign in multiple sclerosis by treatment with weak electromagnetic fields.
Topics: Adult; Axons; Brain; Demyelinating Diseases; Electromagnetic Phenomena; Female; Humans; Male; Melato | 1995 |
Multiple sclerosis: the role of puberty and the pineal gland in its pathogenesis.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Black People; Endocrine System Diseases; Female; Human | 1993 |
Nocturnal melatonin secretion in multiple sclerosis patients with affective disorders.
Topics: Adult; Aged; Circadian Rhythm; Depressive Disorder; Female; Humans; Lithium Carbonate; Male; Melaton | 1993 |
Long term beneficial effects of weak electromagnetic fields in multiple sclerosis.
Topics: Adult; Electromagnetic Fields; Evoked Potentials, Visual; Female; Humans; Magnetics; Melatonin; Mult | 1995 |
Reversal of alexia in multiple sclerosis by weak electromagnetic fields.
Topics: Adult; Brain; Dyslexia, Acquired; Electromagnetic Fields; Female; Humans; Magnetics; Melatonin; Midd | 1995 |
The pineal gland, cataplexy, and multiple sclerosis.
Topics: Cataplexy; Emotions; Humans; Melatonin; Multiple Sclerosis; Muscle Tonus; Pineal Gland; Serotonin; S | 1995 |
Resolution of sleep paralysis by weak electromagnetic fields in a patient with multiple sclerosis.
Topics: Adult; Circadian Rhythm; Electromagnetic Fields; Female; Humans; Melatonin; Multiple Sclerosis; Para | 1997 |
Successful treatment of multiple sclerosis with magnetic fields.
Topics: Brain; Brain Diseases; Chronic Disease; Demyelinating Diseases; Electromagnetic Fields; Female; Huma | 1992 |
The pineal gland and the clinical course of multiple sclerosis.
Topics: Calcinosis; Female; Humans; Melatonin; Middle Aged; Multiple Sclerosis; Pineal Gland; Postpartum Per | 1992 |
8 trials available for melatonin and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
A Randomized Control Trial Study to Determine the Effect of Melatonin on Serum Levels of IL-1β and TNF-α in Patients with Multiple Sclerosis.
Topics: Adult; Double-Blind Method; Female; Humans; Interleukin-1beta; Male; Melatonin; Multiple Sclerosis; | 2019 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
Protocol for a randomized, double blind, placebo controlled, crossover trial of Melatonin for treatment of Nocturia in adults with Multiple Sclerosis (MeNiMS).
Topics: Adult; Central Nervous System Depressants; Clinical Protocols; Cross-Over Studies; Double-Blind Meth | 2017 |
Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS).
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Melatonin; Middle Aged; | 2018 |
Influence of melatonin supplementation on serum antioxidative properties and impact of the quality of life in multiple sclerosis patients.
Topics: Adjuvants, Immunologic; Adult; Antioxidants; Dietary Supplements; Female; Glatiramer Acetate; Humans | 2014 |
Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone.
Topics: Adult; Antioxidants; Brain; Dietary Supplements; Fatigue Syndrome, Chronic; Female; Homocysteine; Hu | 2016 |
[Effect of melatonin on activity of superoxide dismutase (CuZn-SOD) in erythrocytes of patients during short- and long-term hypokinesis].
Topics: Administration, Oral; Aged; Drug Administration Schedule; Erythrocyte Count; Erythrocytes; Humans; H | 2010 |
56 other studies available for melatonin and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Protective effects of melatonin on changes occurring in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
Topics: Animals; Biomarkers; Encephalomyelitis, Autoimmune, Experimental; Humans; Male; Melatonin; Mice; Mic | 2022 |
PDK4 Inhibition Ameliorates Melatonin Therapy by Modulating Cerebral Metabolism and Remyelination in an EAE Demyelinating Mouse Model of Multiple Sclerosis.
Topics: Animals; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Lactic Acid; Melatonin | 2022 |
Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis.
Topics: Animals; Biomarkers; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Glatiramer Acetate; Int | 2022 |
Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway.
Topics: Animals; Biological Factors; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Hu | 2022 |
Inhibiting nighttime melatonin and boosting cortisol increase patrolling monocytes, phagocytosis, and myelination in a murine model of multiple sclerosis.
Topics: Animals; Cell Differentiation; Demyelinating Diseases; Disease Models, Animal; Hydrocortisone; Melat | 2023 |
Sleep disturbance and cognitive decline in multiple sclerosis patients with isolated optic neuritis as the first demyelinating event.
Topics: Adult; Biomarkers; Cognitive Dysfunction; Disease Progression; Enzyme-Linked Immunosorbent Assay; Fe | 2020 |
Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis.
Topics: Adult; Circadian Rhythm; Female; Free Radical Scavengers; Humans; Male; Melatonin; Middle Aged; Mult | 2019 |
Neuroprotective Effects of Melatonin during Demyelination and Remyelination Stages in a Mouse Model of Multiple Sclerosis.
Topics: Animals; Antioxidants; Cuprizone; Female; Interleukin-1beta; Locomotion; Male; Melatonin; Mice; Mult | 2020 |
Melatonin improves memory defects in a mouse model of multiple sclerosis by up-regulating cAMP-response element-binding protein and synapse-associated proteins in the prefrontal cortex.
Topics: Animals; Behavior, Animal; Cuprizone; Cyclic AMP Response Element-Binding Protein; Disease Models, A | 2020 |
Melatonin and multiple sclerosis.
Topics: Humans; Melatonin; Multiple Sclerosis | 2021 |
Corticosteroid therapy exacerbates the reduction of melatonin in multiple sclerosis.
Topics: Adrenal Cortex Hormones; Animals; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimenta | 2017 |
Oxidative Modification of Blood Serum Proteins in Multiple Sclerosis after Interferon Beta and Melatonin Treatment.
Topics: Adult; Blood Proteins; Female; Humans; Interferon-beta; Male; Melatonin; Multiple Sclerosis; Oxidati | 2017 |
Melatonin therapy reduces the risk of osteoporosis and normalizes bone formation in multiple sclerosis.
Topics: Adult; Animals; Biomarkers; Calcitonin; Calcium; Case-Control Studies; Encephalomyelitis, Autoimmune | 2018 |
Spasticity Treatment Ameliorates the Efficacy of Melatonin Therapy in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model of Multiple Sclerosis.
Topics: Animals; Baclofen; Biomarkers; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Exp | 2018 |
A comparative study of melatonin and immunomodulatory therapy with interferon beta and glatiramer acetate in a mouse model of multiple sclerosis.
Topics: Animals; Glatiramer Acetate; Immunomodulation; Interferon-beta; Male; Melatonin; Mice; Multiple Scle | 2021 |
Protective effects of melatonin against mitochondrial injury in a mouse model of multiple sclerosis.
Topics: Animals; Antioxidants; Cuprizone; Cyclooxygenase 2; Disease Models, Animal; Gene Expression Regulati | 2014 |
Melatonin acts as antioxidant and improves sleep in MS patients.
Topics: Adult; Antioxidants; Case-Control Studies; Female; Humans; Male; Melatonin; Middle Aged; Multiple Sc | 2014 |
Melatonin treatment improves primary progressive multiple sclerosis: a case report.
Topics: Adult; Female; Humans; Melatonin; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive | 2015 |
Disruption of melatonin circadian rhythm production is related to multiple sclerosis severity: A preliminary study.
Topics: Adult; Chronobiology Disorders; Creatinine; Cytokines; Enzyme-Linked Immunosorbent Assay; Humans; Me | 2015 |
Melatonin Lulling Th17 Cells to Sleep.
Topics: Animals; Female; Humans; Male; Melatonin; Multiple Sclerosis | 2015 |
Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses.
Topics: Animals; Basic-Leucine Zipper Transcription Factors; CCAAT-Enhancer-Binding Proteins; Cell Different | 2015 |
Evidence for possible role of melatonin in reducing oxidative stress in multiple sclerosis through its effect on SIRT1 and antioxidant enzymes.
Topics: Adult; Antioxidants; Catalase; Cell Survival; Cells, Cultured; Female; Gene Expression Regulation; H | 2016 |
Melatonin enhances interleukin-10 expression and suppresses chemotaxis to inhibit inflammation in situ and reduce the severity of experimental autoimmune encephalomyelitis.
Topics: Animals; Cell Proliferation; Cells, Cultured; Chemotaxis; Disease Progression; Encephalomyelitis, Au | 2016 |
Changes in Serum Ceruloplasmin Levels Based on Immunomodulatory Treatments and Melatonin Supplementation in Multiple Sclerosis Patients.
Topics: Adult; Antioxidants; Biomarkers; C-Reactive Protein; Case-Control Studies; Ceruloplasmin; Dietary Su | 2016 |
Efficacy of N-Acetylserotonin and Melatonin in the EAE Model of Multiple Sclerosis.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Femal | 2016 |
Melatonin exacerbates acute experimental autoimmune encephalomyelitis by enhancing the serum levels of lactate: A potential biomarker of multiple sclerosis progression.
Topics: Animals; Biomarkers; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Lacti | 2017 |
A new track for understanding the pathogenesis of multiple sclerosis: from the perspective of early developmental deficit caused by the potential 5-HT deficiency in individuals in high-latitude areas.
Topics: Altitude; Humans; Melatonin; Models, Theoretical; Multiple Sclerosis; Serotonin | 2008 |
The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis.
Topics: Acute Disease; Adult; Circadian Rhythm; Comorbidity; Depressive Disorder, Major; Disability Evaluati | 2008 |
Prenatal corticosteroids: pretermer outcomes, stress, schizophrenia, multiple sclerosis and the developmental role of melatonin and vitamin D3.
Topics: Cholecalciferol; Dietary Supplements; Female; Humans; Hydrocortisone; Infant, Newborn; Melatonin; Mu | 2010 |
Sunlight and MS.
Topics: Humans; Melatonin; Multiple Sclerosis; Sunlight; Vitamin D | 2011 |
Multiple sclerosis and seizures: possible role of Helicobacter pylori.
Topics: Anticonvulsants; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interleukin-18; Melatonin; Multiple S | 2011 |
[The effects of whole-body cryotherapy and melatonin supplementation on total antioxidative status and some antioxidative enzymes in multiple sclerosis patients].
Topics: Adult; Antioxidants; Catalase; Cryotherapy; Dietary Supplements; Erythrocytes; Female; Humans; Male; | 2011 |
Melatonin pathway genes are associated with progressive subtypes and disability status in multiple sclerosis among Finnish patients.
Topics: Case-Control Studies; Disability Evaluation; Female; Finland; Genetic Predisposition to Disease; Gen | 2012 |
The influence of immunomodulation on psycho-neuroimmunological functions in benign multiple sclerosis.
Topics: Adult; Cognition Disorders; Depressive Disorder; Disability Evaluation; Evoked Potentials, Visual; F | 2004 |
A potential multiple resonance mechanism by which weak magnetic fields affect molecules and medical problems: the example of melatonin and experimental "multiple sclerosis".
Topics: Animals; Humans; Magnetics; Melatonin; Multiple Sclerosis; Rats | 2006 |
Rapid normalization of visual evoked potentials by picoTesla range magnetic fields in chronic progressive multiple sclerosis.
Topics: Brain; Chronic Disease; Evoked Potentials, Visual; Humans; Magnetic Resonance Imaging; Magnetics; Me | 1994 |
Improvement by picoTesla range magnetic fields of perceptual-motor performance and visual memory in a patient with chronic progressive multiple sclerosis.
Topics: Chronic Disease; Electromagnetic Fields; Humans; Male; Melatonin; Memory; Middle Aged; Multiple Scle | 1994 |
The relationship between melatonin secretion and serum cholesterol in patients with multiple sclerosis.
Topics: Adult; Age of Onset; Cholesterol; Cohort Studies; Female; Humans; Hypercholesterolemia; Male; Melato | 1994 |
The co-occurrence of multiple sclerosis and migraine headache: the serotoninergic link.
Topics: Adult; Aged; Blood-Brain Barrier; Brain; Calcinosis; Female; Humans; Melatonin; Methylprednisolone; | 1994 |
Relationship of nocturnal melatonin levels to duration and course of multiple sclerosis.
Topics: Adult; Age of Onset; Aged; Female; Humans; Male; Melatonin; Middle Aged; Multiple Sclerosis; Pineal | 1994 |
Resolution of longstanding symptoms of multiple sclerosis by application of picoTesla range magnetic fields.
Topics: Brain; Electromagnetic Fields; Female; Humans; Magnetic Resonance Imaging; Melatonin; Middle Aged; M | 1993 |
Demyelination as an epiphenomenon in multiple sclerosis.
Topics: Animals; Demyelinating Diseases; Evoked Potentials; Humans; Magnetics; Melatonin; Models, Neurologic | 1993 |
Multiple sclerosis: the role of the pineal gland in its timing of onset and risk of psychiatric illness.
Topics: Adolescent; Adult; Age of Onset; Aged; Female; Humans; Male; Melanins; Melatonin; Mental Disorders; | 1993 |
Multiple sclerosis: sunlight, diet, immunology and aetiology.
Topics: Autoimmunity; Central Nervous System; Diet; Humans; Inflammation Mediators; Leukotrienes; Melatonin; | 1996 |
Weak electromagnetic fields increase the amplitude of the pattern reversal VEP response in patients with multiple sclerosis.
Topics: Electromagnetic Fields; Evoked Potentials, Visual; Female; Humans; Melatonin; Middle Aged; Multiple | 1996 |
Bidirectional effect of electromagnetic fields on ketanserin-induced yawning in patients with multiple sclerosis: the role of melatonin.
Topics: Adult; Electromagnetic Fields; Female; Humans; Ketanserin; Male; Melatonin; Middle Aged; Multiple Sc | 1996 |
Diurnal variations in vision and relations to circadian melatonin secretion in multiple sclerosis.
Topics: Body Temperature; Circadian Rhythm; Evoked Potentials, Visual; Humans; Male; Melatonin; Middle Aged; | 1995 |
Resolution of dysarthria in multiple sclerosis by treatment with weak electromagnetic fields.
Topics: Brain; Dysarthria; Electromagnetic Fields; Female; gamma-Aminobutyric Acid; Humans; Magnetic Resonan | 1995 |
Melanin, melatonin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: a rationale for light therapy in multiple sclerosis.
Topics: Animals; Autoimmune Diseases; Demyelinating Diseases; Encephalomyelitis, Autoimmune, Experimental; H | 1995 |
Treatment with weak electromagnetic fields attenuates carbohydrate craving in a patients with multiple sclerosis.
Topics: Appetite; Brain Chemistry; Dietary Carbohydrates; Electromagnetic Fields; Female; Humans; Melatonin; | 1996 |
Electromagnetic fields for treatment of multiple sclerosis.
Topics: Adolescent; Adult; Age of Onset; Electromagnetic Fields; Female; Humans; Male; Melatonin; Middle Age | 1996 |
Suicidal behavior is attenuated in patients with multiple sclerosis by treatment with electromagnetic fields.
Topics: Adult; Circadian Rhythm; Depressive Disorder; Electromagnetic Fields; Female; Humans; Melatonin; Mid | 1996 |
A proposed role for nerve growth factor in the etiology of multiple sclerosis.
Topics: Animals; Cerebrovascular Circulation; Female; Humans; Hypothalamo-Hypophyseal System; Immune System; | 1998 |
The pineal gland in multiple sclerosis.
Topics: Adult; Calcinosis; Choroid Plexus; Female; Humans; Male; Melatonin; Middle Aged; Multiple Sclerosis; | 1991 |
Coexisting bipolar affective disorder and multiple sclerosis: the role of the pineal gland.
Topics: Autoimmune Diseases; Bipolar Disorder; Circadian Rhythm; Depression; Humans; Immune Tolerance; Light | 1991 |
Multiple sclerosis--is research on the wrong track?
Topics: Ergotamine; Humans; Light; Melatonin; Multiple Sclerosis | 1991 |